Medication info
Teloduo Tablet 40/5 mg

Teloduo Tablet 40/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201907255 · Approved 2019.10.15 · Insurance code 648603890

Summary

Main use
Treatment of hypertension; improvement of dyslipidemia; prevention of cardiovascular disease and inhibition of arteriosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of dyslipidemia; prevention of cardiovascular disease and inhibition of arteriosclerosis progression

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
View approved original text

This medication is used for patients who need to take telmisartan and rosuvastatin together. Telmisartan primarily helps treat essential hypertension and reduces the risk of cardiovascular diseases. It is particularly used in high-risk groups such as those over 55 years old with heart diseases, strokes, or end-organ damage due to diabetes to lower the risk of myocardial infarction, stroke, and mortality from cardiovascular diseases. Rosuvastatin is used as an adjunct treatment when dietary management for hypercholesterolemia and dyslipidemia is insufficient. It also helps delay the progression of atherosclerosis due to hypercholesterolemia and reduce the risk of cardiovascular diseases, strokes, myocardial infarction, and vascular revascularization procedures. Therefore, this medication is used to manage both hypertension and hyperlipidemia simultaneously to improve cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be given to individuals with hypersensitivity to this medication, to pregnant or breastfeeding women, and to fertile women who are not using proper contraceptive methods. Patients with severely impaired liver function, those with biliary obstruction or cholestasis, unexplained increases in liver enzyme levels, and patients with muscle disease should not use this medication. Use is also prohibited in patients with very poor kidney function or when combined with certain medications. Caution should be exercised in elderly patients, those with hyperkalemia, and patients with mild to moderate liver impairment; liver function and muscle status should be periodically monitored during treatment. This medication may cause serious muscle disorders such as muscle pain, myopathy, and, rarely, rhabdomyolysis, so consult a doctor immediately if muscle pain or weakness occurs. As a blood pressure-lowering agent, it may cause hypotension, dizziness, fainting, etc., especially during the initial administration, so caution is required. Various side effects such as liver dysfunction, hyperkalemia, and worsening kidney function may occur, making regular blood tests and clinical observation important. As there may be drug interactions, inform healthcare providers about any other medications being taken. This medication may cause drowsiness or dizziness when driving or operating machinery, so caution is needed. Keep out of reach of children and do not transfer to other containers for safety.

Side effects

Headache, postural dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, ALT elevation, painful urination, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver dysfunction, hepatic impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, edema, decreased libido, facial edema, alopecia, conjunctivitis, sounds in the ear, petechiae, palpitations, fatigue, nausea, lack of efficacy, headache, dizziness, cough, dyspepsia, palpitations, myalgia, elevated CK, constipation, increased AST, weakness, joint pain, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, widespread pain, muscle cramps, gout, erectile dysfunction, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, memory impairment, amnesia, memory loss, cognitive dysfunction, confusion, severe muscle weakness, ocular myasthenia, hypotension, tachycardia, bradycardia, acute renal failure, shock, loss of consciousness, hepatic dysfunction, jaundice, anaphylactic-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, headache, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, edema, decreased libido, facial edema, rash, alopecia, conjunctivitis, sounds in the ear, petechiae, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, memory impairment, amnesia, memory loss, cognitive dysfunction, confusion

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to avoid exposure to air or moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius. This helps to preserve the effectiveness and safety of the medication for a longer period.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.